vs
Side-by-side financial comparison of ASTRONICS CORP (ATRO) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
ASTRONICS CORP is the larger business by last-quarter revenue ($240.1M vs $196.9M, roughly 1.2× Pacira BioSciences, Inc.). On growth, ASTRONICS CORP posted the faster year-over-year revenue change (15.1% vs 5.1%). Pacira BioSciences, Inc. produced more free cash flow last quarter ($43.5M vs $15.8M). Over the past eight quarters, ASTRONICS CORP's revenue compounded faster (13.9% CAGR vs 8.5%).
Astronics Corporation is an American aerospace electronics corporation founded in 1968, headquartered in East Aurora, New York. It is traded on NASDAQ as Nasdaq: ATRO. It is known for lighting and electronics integrations on military, commercial, and business aircraft and semiconductor test systems.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
ATRO vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $240.1M | $196.9M |
| Net Profit | — | — |
| Gross Margin | 33.3% | 79.5% |
| Operating Margin | 14.8% | 1.2% |
| Net Margin | — | — |
| Revenue YoY | 15.1% | 5.1% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.82 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $240.1M | $196.9M | ||
| Q3 25 | $211.4M | $179.5M | ||
| Q2 25 | $204.7M | $181.1M | ||
| Q1 25 | $205.9M | $168.9M | ||
| Q4 24 | $208.5M | $187.3M | ||
| Q3 24 | $203.7M | $168.6M | ||
| Q2 24 | $198.1M | $178.0M | ||
| Q1 24 | $185.1M | $167.1M |
| Q4 25 | — | — | ||
| Q3 25 | $-11.1M | $5.4M | ||
| Q2 25 | $1.3M | $-4.8M | ||
| Q1 25 | $9.5M | $4.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-11.7M | $-143.5M | ||
| Q2 24 | $1.5M | $18.9M | ||
| Q1 24 | $-3.2M | $9.0M |
| Q4 25 | 33.3% | 79.5% | ||
| Q3 25 | 30.5% | 80.9% | ||
| Q2 25 | 25.8% | 77.4% | ||
| Q1 25 | 29.5% | 79.7% | ||
| Q4 24 | 29.8% | 78.7% | ||
| Q3 24 | 27.1% | 76.9% | ||
| Q2 24 | 28.0% | 75.1% | ||
| Q1 24 | 25.7% | 71.6% |
| Q4 25 | 14.8% | 1.2% | ||
| Q3 25 | 10.9% | 3.5% | ||
| Q2 25 | 2.3% | 4.7% | ||
| Q1 25 | 6.4% | 1.2% | ||
| Q4 24 | 4.3% | 13.2% | ||
| Q3 24 | 4.1% | -82.8% | ||
| Q2 24 | 3.8% | 15.9% | ||
| Q1 24 | 0.9% | 7.9% |
| Q4 25 | — | — | ||
| Q3 25 | -5.2% | 3.0% | ||
| Q2 25 | 0.6% | -2.7% | ||
| Q1 25 | 4.6% | 2.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | -5.8% | -85.1% | ||
| Q2 24 | 0.8% | 10.6% | ||
| Q1 24 | -1.7% | 5.4% |
| Q4 25 | $0.82 | $0.05 | ||
| Q3 25 | $-0.31 | $0.12 | ||
| Q2 25 | $0.04 | $-0.11 | ||
| Q1 25 | $0.26 | $0.10 | ||
| Q4 24 | $-0.07 | $0.38 | ||
| Q3 24 | $-0.34 | $-3.11 | ||
| Q2 24 | $0.04 | $0.39 | ||
| Q1 24 | $-0.09 | $0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $18.2M | $238.4M |
| Total DebtLower is stronger | — | $372.2M |
| Stockholders' EquityBook value | $140.1M | $693.1M |
| Total Assets | $706.7M | $1.3B |
| Debt / EquityLower = less leverage | — | 0.54× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $18.2M | $238.4M | ||
| Q3 25 | $13.5M | $246.3M | ||
| Q2 25 | $13.5M | $445.9M | ||
| Q1 25 | $24.8M | $493.6M | ||
| Q4 24 | $9.3M | $484.6M | ||
| Q3 24 | $5.2M | $453.8M | ||
| Q2 24 | $2.9M | $404.2M | ||
| Q1 24 | $5.3M | $325.9M |
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $140.1M | $693.1M | ||
| Q3 25 | $108.9M | $727.2M | ||
| Q2 25 | $271.6M | $757.8M | ||
| Q1 25 | $266.8M | $798.5M | ||
| Q4 24 | $256.1M | $778.3M | ||
| Q3 24 | $249.2M | $749.6M | ||
| Q2 24 | $257.9M | $879.3M | ||
| Q1 24 | $251.7M | $892.2M |
| Q4 25 | $706.7M | $1.3B | ||
| Q3 25 | $682.2M | $1.3B | ||
| Q2 25 | $646.7M | $1.5B | ||
| Q1 25 | $662.2M | $1.6B | ||
| Q4 24 | $648.8M | $1.6B | ||
| Q3 24 | $651.6M | $1.5B | ||
| Q2 24 | $644.9M | $1.6B | ||
| Q1 24 | $630.0M | $1.6B |
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $27.6M | $43.7M |
| Free Cash FlowOCF − Capex | $15.8M | $43.5M |
| FCF MarginFCF / Revenue | 6.6% | 22.1% |
| Capex IntensityCapex / Revenue | 4.9% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | $136.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.6M | $43.7M | ||
| Q3 25 | $34.2M | $60.8M | ||
| Q2 25 | $-7.6M | $12.0M | ||
| Q1 25 | $20.6M | $35.5M | ||
| Q4 24 | $26.4M | $33.1M | ||
| Q3 24 | $8.4M | $53.9M | ||
| Q2 24 | $-6.3M | $53.2M | ||
| Q1 24 | $2.0M | $49.1M |
| Q4 25 | $15.8M | $43.5M | ||
| Q3 25 | $21.0M | $57.0M | ||
| Q2 25 | $-12.2M | $9.3M | ||
| Q1 25 | $18.5M | $26.9M | ||
| Q4 24 | $23.2M | $31.0M | ||
| Q3 24 | $6.5M | $49.8M | ||
| Q2 24 | $-8.1M | $51.6M | ||
| Q1 24 | $439.0K | $46.3M |
| Q4 25 | 6.6% | 22.1% | ||
| Q3 25 | 9.9% | 31.7% | ||
| Q2 25 | -6.0% | 5.1% | ||
| Q1 25 | 9.0% | 15.9% | ||
| Q4 24 | 11.1% | 16.6% | ||
| Q3 24 | 3.2% | 29.6% | ||
| Q2 24 | -4.1% | 29.0% | ||
| Q1 24 | 0.2% | 27.7% |
| Q4 25 | 4.9% | 0.1% | ||
| Q3 25 | 6.2% | 2.2% | ||
| Q2 25 | 2.2% | 1.5% | ||
| Q1 25 | 1.0% | 5.1% | ||
| Q4 24 | 1.5% | 1.1% | ||
| Q3 24 | 0.9% | 2.4% | ||
| Q2 24 | 0.9% | 0.9% | ||
| Q1 24 | 0.9% | 1.7% |
| Q4 25 | — | — | ||
| Q3 25 | — | 11.20× | ||
| Q2 25 | -5.81× | — | ||
| Q1 25 | 2.17× | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -4.08× | 2.82× | ||
| Q1 24 | — | 5.47× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ATRO
| Product Line Electrical Power And Motion | $113.8M | 47% |
| Product Line Avionics | $32.0M | 13% |
| Military Aircraft | $28.0M | 12% |
| General Aviation | $22.3M | 9% |
| Government And Defense | $20.5M | 9% |
| Product Line Systems Certification | $13.2M | 6% |
| Product Line Structures | $3.7M | 2% |
| Product Line Other | $2.3M | 1% |
PCRX
| EXPAREL | $155.8M | 79% |
| ZILRETTA | $33.0M | 17% |
| Iovera | $7.0M | 4% |
